Novavax has received full marketing authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its prototype Covid-19 vaccine Nuvaxovid (NVX-CoV2373).

The vaccine is approved for individuals aged 12 years and above for active immunisation to prevent Covid-19.

MHRA authorised the vaccine based on data from two Phase III studies, PREVENT-19 carried out in the US and Mexico, a Phase III study in the UK and a Phase IIa/b trial in South Africa.

Novavax has shown the safety and efficacy of its prototype vaccine as a primary series in individuals aged 12 and above, along with its safety and immunogenicity as a booster in those aged 18 and above.

The protein-based vaccine NVX-CoV2373 is produced by creating copies of the surface spike protein of the SARS-CoV-2 virus that causes Covid-19.

With the recombinant nanoparticle technology of Novavax, the non-infectious spike protein acts as the antigen that primes the immune system to recognise the virus.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The vaccine comes in a liquid form that is ready for use and should be stored between 2°C and 8°C.

Novavax president and CEO John Jacobs stated: “Full marketing authorisation of our prototype Covid-19 vaccine in the UK is a stepping stone to enable authorisation of updated strains of our vaccine in the future.

“We are working with the MHRA to provide the information needed for the rapid review of our updated protein-based non-mRNA Covid-19 vaccine as an important step to ensuring access to vaccine options in the UK this coming vaccination season.”